Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25962302 | 0.83 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NPC1HPGD | |
| SCHEMBL20381510 | 0.82 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2NPC1HSD17B10HPGD | |
| SCHEMBL16591610 | 0.81 | CYP2D6 (0.45) | ALDH1A1SMN1; SMN2NPC1HSD11B1EPHX2 | |
| SCHEMBL22150221 | 0.81 | ALDH1A1 (0.45) | ALDH1A1GNAI3GNAO1GNAI1SMN1; SMN2 | |
| SCHEMBL12892362 | 0.78 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2NPC1HPGD | |
| SCHEMBL13451999 | 0.77 | FAAH (0.47) | ALDH1A1GNAI3GNAO1GNAI1NPC1 | |
| SCHEMBL4487574 | 0.76 | EPHX2 (0.51) | ALDH1A1GNAI3GNAO1GNAI1NPC1 | |
| SCHEMBL20939048 | 0.75 | GNAI3 (0.51) | ALDH1A1GNAI3GNAO1GNAI1NPC1 | |
| SCHEMBL12424480 | 0.74 | ALDH1A1 (0.42) | ALDH1A1GNAI3GNAO1GNAI1NPC1 | |
| SCHEMBL8354763 | 0.74 | FKBP1A (0.50) | ALDH1A1SMN1; SMN2NPC1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008334-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200255446-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255446-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | ALDH1A1 2792/4885GNAI3 209/4885GNAO1 1080/4885 |
| US-11008334-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | ALDH1A1 2792/4885GNAI3 209/4885GNAO1 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.